Mostrar el registro sencillo del ítem

dc.creatorNtellas P., Dardiotis E., Sevdali E., Siokas V., Aloizou A.-M., Tsinti G., Germenis A.E., Hadjigeorgiou G.M., Eibel H., Speletas M.en
dc.date.accessioned2023-01-31T09:40:51Z
dc.date.available2023-01-31T09:40:51Z
dc.date.issued2020
dc.identifier10.1016/j.msard.2019.101422
dc.identifier.issn22110348
dc.identifier.urihttp://hdl.handle.net/11615/77340
dc.description.abstractRecent studies implicate B cells in multiple sclerosis (MS) pathogenesis, and consequently, several molecules participating in B cell survival and proliferation, including B-cell activating factor (BAFF), have recently been analyzed in MS patients. BAFF mediates its function through binding to three receptors; among them, its interaction with the BAFF receptor (BAFFR) is crucial in mediating its survival function. Interestingly, two common polymorphisms of the TNFRSF13C gene, encoding BAFFR, P21R (rs77874543) and H159Y (rs61756766), have been reported to affect BAFFR assembly and signaling. In order to evaluate the possible contribution of BAFFR in MS pathogenesis and/or phenotype, we analyzed both TNFRSF13C/BAFFR polymorphisms in 486 MS patients in relation to their disease severity, their disability status and the age of disease onset and duration. As control group, we used allele frequencies extracted from the Exome Aggregation Consortium (ExAC) Browser. Interestingly, we found a higher prevalence of the H159Y polymorphism in MS patients, suggesting that enhanced BAFFR-signaling might contribute to the disease pathogenesis. © 2019 Elsevier B.V.en
dc.language.isoenen
dc.sourceMultiple Sclerosis and Related Disordersen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85073934023&doi=10.1016%2fj.msard.2019.101422&partnerID=40&md5=5e5edf7b7d7cd0e6d0d5f5033304629b
dc.subjectadulten
dc.subjectageden
dc.subjectArticleen
dc.subjectBAFFR P21R geneen
dc.subjectcohort analysisen
dc.subjectcontrolled studyen
dc.subjectdisabilityen
dc.subjectdisease durationen
dc.subjectdisease severityen
dc.subjectfemaleen
dc.subjectgeneen
dc.subjectgene frequencyen
dc.subjectgenetic polymorphismen
dc.subjectH159Y geneen
dc.subjecthumanen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmultiple sclerosisen
dc.subjectonset ageen
dc.subjectP21R geneen
dc.subjectpathogenesisen
dc.subjectphenotypeen
dc.subjectprevalenceen
dc.subjectsignal transductionen
dc.subjectTNFRSF13C geneen
dc.subjectB lymphocyteen
dc.subjectgenetic polymorphismen
dc.subjectgeneticsen
dc.subjectimmunologyen
dc.subjectmetabolismen
dc.subjectmultiple sclerosisen
dc.subjectB cell activating factoren
dc.subjectB cell activating factor receptoren
dc.subjectTNFRSF13C protein, humanen
dc.subjectTNFSF13B protein, humanen
dc.subjectAdulten
dc.subjectAge of Onseten
dc.subjectB-Cell Activating Factoren
dc.subjectB-Cell Activation Factor Receptoren
dc.subjectB-Lymphocytesen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMultiple Sclerosisen
dc.subjectPolymorphism, Geneticen
dc.subjectSignal Transductionen
dc.subjectElsevier B.V.en
dc.titleTNFRSF13C/BAFFR P21R and H159Y polymorphisms in multiple sclerosisen
dc.typejournalArticleen


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem